Compare Invesco WilderHill Clean Energy ETF (PBW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco WilderHill Clean Energy ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Invesco WilderHill Clean Energy ETF trades at $28.29 (market cap $347.46M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 368.8× Invesco WilderHill Clean Energy ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco WilderHill Clean Energy ETF for 46 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PBW | VRTX | |
|---|---|---|
Market Cap | $347.46M | $128.16B |
Volume | 413,698 | 806,603 |
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $557.96 |
52-Week Low | $28.29 | $407.37 |
Typical Hold Time | 46 Days | 120 Days |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBW, the Invesco WilderHill Clean Energy ETF, trades at $28.92, down 2.89% today amid a bearish technical signal from moving averages. The ETF's unique selection criteria prioritize ecological factors over financial metrics, resulting in concentrated exposure to the clean energy sector. Recent institutional selling, including a 96.3% reduction by IFP Advisors Inc. in Q2 2026 (SEC filing, September 18, 2026), reflects cautious sentiment despite long-term growth drivers like energy security and data center demand.
Outlook remains challenged by near-term volatility and sector underperformance versus broad markets, though global investment in clean energy offers structural tailwinds. Key risks include oil price swings, Fed policy impacts, and lack of diversification. Investors face a trade-off between speculative growth potential and elevated sensitivity to macroeconomic shifts.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
